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Pathologists (ARUP), Institute for Clinical and Experimental Pathology and the 2Department of 
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Objective: To compare the results obtained by two separate reference laboratories (Prometheus 
Laboratories, San Diego, CA vs ARUP Laboratories, Salt Lake City, UT) for serological assays 
utilized in the diagnosis and differentiation of Crohn's disease (CD) and ulcerative colitis (UC), and 
to assess the clinical utility of the outer-membrane porin C (OmpC) IgA assay in IBD. 
Methods: Sera from 197 patients suspected of having IBD were included in the study. Serological 
assays for anti-Saccharomyces cerevisiae antibodies (ASCA) IgA and IgG were performed using 
enzyme immunoassay (EIA) techniques by both laboratories. Atypical perinuclear neutrophil 
cytoplasmic antibody (PANCA) IgG was detected using indirect fluorescent antibody (IF A) 
techniques. Prometheus Laboratories utilized the DNAse-I digest method for the detection of 
pANCA. ARUP Laboratories employed the standard IF A method using ethanol and formalin-fixed 
neutrophils for the detection of pANCA. The OmpC IgA assay is performed only by Prometheus 
Laboratories and is promoted as a means of detecting patients with CD who are ASCA negative. 
All patient samples included in this study were processed according to the University of Utah 
Institutional Review Board (IRB) approved protocol #13433 and meet the Health Information 
Portability and Accountability Act (HIP AA) patient confidentiality guidelines. No additional 
patient information was available for these sera. 
Results: The ASCA and pANCA assays employed at ARUP Laboratories have been approved by 
the Food and Drug Administration (FDA) for in vitro diagnostic use and were used as the reference 
method for statistical comparisons. Percent agreement between the two laboratories was 93.4% for 
ASCA IgA, 90.9% for ASCA IgG, and 86.8% for pANCA IgG. The ASCA IgG assay performed 
at Prometheus showed low sensitivity (43.8%) when compared to the FDA approved assay 
employed at ARUP Laboratories. This finding is in agreement with the Vermeire study 
(Gastroenterology, 2001;120:827-833). Prometheus detected pANCA in 24 sera that were negative 
by the FDA approved method performed at ARUP. Further testing of these pANCA discrepant sera 
showed 13 (54.2%) to contain antibodies against one or more of other known neutrophil and nuclear 
antigens (PR3, dsDNA, RNP, Histone, Chromatin). There were 25 sera with ASCA 
negative/OmpC positive results reported by Prometheus testing. Three of these sera were ASCA 
positive (1 for IgA, 1 for IgG, 1 for both IgG and IgA) by the FDA approved assays employed at 
ARUP Laboratories. Fifteen of these 25 (60.0%) ASCA negative/OmpC positive sera gave positive 
results for pANCA IgG (9 by both laboratories, 5 by Prometheus only, and 1 by ARUP only). Note: 
Atypical pANCA is found primarily in IBD patients with UC (70.0%) and to a lesser extent in CD 
(20.0%). 
Conclusion: We conclude that the ASCA and pANCA assays showed good agreement between 
the two laboratories, but the ASCA IgG and pANCA approved assays employed at ARUP 
Laboratories were more sensitive and specific (respectively) than those performed at 
Prometheus. The data for ASCA negative/OmpC positive sera suggest that OmpC IgA may be 
more prevalent and useful in patients with DC, but seems to have little diagnostic value in CD. 
